Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 10.61 USD 3.71% Market Closed
Market Cap: 1B USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Avadel Pharmaceuticals PLC
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Avadel Pharmaceuticals PLC
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Inventory
$16.1m
CAGR 3-Years
N/A
CAGR 5-Years
48%
CAGR 10-Years
10%
Perrigo Company PLC
NYSE:PRGO
Inventory
$1.1B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
6%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Inventory
$539.3m
CAGR 3-Years
-22%
CAGR 5-Years
50%
CAGR 10-Years
30%
Cosmo Pharmaceuticals NV
SIX:COPN
Inventory
€13.9m
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
12%
Ovoca Bio PLC
LSE:OVB
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals
Economic Moat
None

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
17.97 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Avadel Pharmaceuticals PLC's Inventory?
Inventory
16.1m USD

Based on the financial report for Sep 30, 2024, Avadel Pharmaceuticals PLC's Inventory amounts to 16.1m USD.

What is Avadel Pharmaceuticals PLC's Inventory growth rate?
Inventory CAGR 10Y
10%

Over the last year, the Inventory growth was 205%.

Back to Top